Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26351968 | 0.88 | TGFBR1 (0.46) | KDM4ETGFBR1TYK2JAK2JAK1 | |
| SCHEMBL19030355 | 0.84 | TGFBR1 (0.58) | KDM4ETGFBR1STING1L3MBTL1TYK2 | |
| SCHEMBL23728509 | 0.82 | TGFBR1 (0.52) | KDM4ETGFBR1PDE2A | |
| SCHEMBL359281 | 0.79 | TYK2 (0.53) | KDM4ETGFBR1PDE2AL3MBTL1TYK2 | |
| SCHEMBL461457 | 0.77 | TGFBR1 (0.42) | KDM4ETGFBR1PDE2ASTING1L3MBTL1 | |
| SCHEMBL13975698 | 0.77 | SMPD3 (0.37) | KDM4E | |
| SCHEMBL24422759 | 0.76 | SMPD3 (0.34) | KDM4EPDE2AIRAK4 | |
| SCHEMBL29339727 | 0.76 | SMPD3 (0.57) | KDM4E | |
| SCHEMBL17132579 | 0.76 | SMPD3 (0.38) | PDE2ATYK2IRAK4 | |
| SCHEMBL461050 | 0.76 | FLT3 (0.44) | KDM4ETGFBR1L3MBTL1TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885TGFBR1 1014/4885PDE2A 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.